Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Replimune Group (REPL) has drawn attention after presenting updated clinical data from its IGNYTE phase 2 trial at the ESMO Congress 2025. The study combined RP1 with nivolumab in patients with acral ...

DIY Hacks for your Home Projects!! Trump Warns of Threat to Social Security, Medicare Map reveals most hated foods in the US Judge says Greenpeace must pay $345 million in pipeline lawsuit, cutting ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has ...

PETALING JAYA: The Education Ministry (KPM) tops the list of ministries with the most uncompleted projects, according to the latest Auditor-General’s report. A total of 112 projects under the ministry ...

Python Software Foundation rejects what would be the largest grant ever awarded To accept the grant, it would have to abandon any DEI related activity The National Science Foundation would be able to ...